Molecular therapy for Myocardial Infarction: JunB improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 5/October/2016, 7.38 am

Therapeutic insights into PD-1 pathway blockade for Human cancer therapy: Olea europaea leaf extract (OLE) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down regulation of its target gene, 4/October/2016, 10.35 pm
October 4, 2016
Therapeutic insights into “awakening the sleeping angel” in mutant p53-expressing human tumors: MiR-497 increases the expression of tumor suppressor p53 homologue TAp63γ and induces regression of p53-mutated human tumors via down regulation of its target gene, 5/October/2016, 8.14 am
October 5, 2016
Show all

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: JunB improves myocardial function after myocardial infarction via  up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10)

Significance:

satisfaction-guaranted-if-not-refunded

Satisfaction guaranteed if not refunded

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.

This study suggests, for the first time, a small molecule-based cardiac regeneration therapy. JunB, by increasing the expression of its target gene, it may increase the expression of PNUTS/PPP1R10. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardiomyocyte survival/regeneration.

Thus, by treating myocardial patients with JunB activators, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “JunB activators” may be used to improve cardiac function after myocardial infarction

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Molecular therapy for Myocardial Infarction: JunB improves myocardial function after myocardial infarction via  up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 5/October/2016, 7.38 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation

Amount: $300

Undisclosed information: How JunB  increases the expression of PNUTS/PPP1R10

 Attention: Kindly understand that this idea was posted earlier by us, but then we lost it on our website because somebody had hacked our website in the second week of Oct, 2015.  We are in the process of recovering our ideas posted earlier, especially from May, 2015 to October, 2015. So, this idea is re-posted for the sake of the researchers.

Comments are closed.